Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysis

Elisa Gelli; Claudia Martinuzzi; Debora Soncini; Concetta Conticello; Francesco Ladisa; Giulia Giorgetti; Dario Truffelli; Isabella Traverso; Francesco Lai; Fabio Guolo; Maurizio Miglino; Antonia Cagnetta; Antonella Laudisi; Sara Aquino; Daniele Derudas; Francesco Di Raimondo; Domenico A. Coviello; Roberto M. Lemoli; Michele Cea

doi:10.1038/s41598-024-79748-7

journal article Open Access Nov 26, 2024

Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysis

Elisa Gelli Claudia Martinuzzi Debora Soncini Concetta Conticello

Francesco Ladisa Giulia Giorgetti Dario Truffelli Isabella Traverso Francesco Lai Fabio Guolo Maurizio Miglino Antonia Cagnetta Antonella Laudisi Sara Aquino Daniele Derudas Francesco Di Raimondo Domenico A. Coviello Roberto M. Lemoli

Michele Cea

Scientific Reports Vol. 14 No. 1 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/s41598-024-79748-7

Topics

No keywords indexed for this article. Browse by subject →

References

44

[1]

Multiple myeloma

Shaji K. Kumar, Vincent Rajkumar, Robert A. Kyle et al.

Nature Reviews Disease Primers 2017 10.1038/nrdp.2017.46

[2]

Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management

S. Vincent Rajkumar

American Journal of Hematology 2020 10.1002/ajh.25791

[3]

Marcon, C. et al. Experts’ consensus on the definition and management of high risk multiple myeloma. Front. Oncol. 12, 1096852 (2022). 10.3389/fonc.2022.1096852

[4]

Larocca, A. et al. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia 32, 1697–1712 (2018). 10.1038/s41375-018-0142-9

[5]

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

David P. Steensma, Rafael Bejar, Siddhartha Jaiswal et al.

Blood 2015 10.1182/blood-2015-03-631747

[6]

Solís-Moruno, M., Batlle-Masó, L., Bonet, N., Aróstegui, J. I. & Casals, F. Somatic genetic variation in healthy tissue and non-cancer diseases. Eur. J. Hum. Genet. 31, 48–54 (2023). 10.1038/s41431-022-01213-8

[7]

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

Siddhartha Jaiswal, Pierre Fontanillas, Jason Flannick et al.

New England Journal of Medicine 2014 10.1056/nejmoa1408617

[8]

Bejar, R. CHIP, ICUS, CCUS and other four-letter words. Leukemia 31, 1869–1871 (2017). 10.1038/leu.2017.181

[9]

Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults

Andrew L. Young, Grant A. Challen, Brenda M. Birmann et al.

Nature Communications 2016 10.1038/ncomms12484

[10]

Coombs, C. C. et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 21, 374-382.e4 (2017). 10.1016/j.stem.2017.07.010

[11]

Gibson, C. J. et al. Clonal Hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J. Clin. Oncol. 35, 1598–1605 (2017). 10.1200/jco.2016.71.6712

[12]

Gillis, N. K. et al. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 18, 112–121 (2017). 10.1016/s1470-2045(16)30627-1

[13]

Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11–30 (2013). 10.3322/caac.21166

[14]

Age-related mutations associated with clonal hematopoietic expansion and malignancies

Mingchao Xie, Charles Lu, Jiayin Wang et al.

Nature Medicine 2014 10.1038/nm.3733

[15]

Dorsheimer, L. et al. Association of mutations contributing to clonal Hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 4, 25–33 (2019). 10.1001/jamacardio.2018.3965

[16]

Miller, P. G. et al. Association of clonal hematopoiesis with chronic obstructive pulmonary disease. Blood 139, 357–368 (2022). 10.1182/blood.2021013531

[17]

Agrawal, M. et al. TET2-mutant clonal hematopoiesis and risk of gout. Blood 140, 1094–1103 (2022). 10.1182/blood.2022015384

[18]

Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease

Siddhartha Jaiswal, Pradeep Natarajan, Alexander J. Silver et al.

New England Journal of Medicine 2017 10.1056/nejmoa1701719

[19]

Miller, P. G. et al. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 5, 2982–2986 (2021). 10.1182/bloodadvances.2021004554

[20]

Bejar, R. et al. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 364, 2496–2506 (2011). 10.1056/nejmoa1013343

[21]

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

New England Journal of Medicine 10.1056/nejmoa1301689

[22]

Papaemmanuil, E. et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616–27 (2013). 10.1182/blood-2013-08-518886

[23]

Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients

Enrica Borsi, Ilaria Vigliotta, Andrea Poletti et al.

Cells 2024 10.3390/cells13080657

[24]

Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma

Tarek H. Mouhieddine, Chidimma Nzerem, Robert Redd et al.

Cancer Research Communications 2023 10.1158/2767-9764.crc-23-0093

[25]

Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant

Tarek H. Mouhieddine, Adam S. Sperling, Robert Redd et al.

Nature Communications 2020 10.1038/s41467-020-16805-5

[26]

Norris, J. R. et al. Correlation of paramagnetic states and molecular structure in bacterial photosynthetic reaction centers: the symmetry of the primary electron donor in Rhodopseudomonas viridis and Rhodobacter sphaeroides R-26. Proc. Natl. Acad. Sci. USA 86, 4335–9 (1989). 10.1073/pnas.86.12.4335

[27]

Becherini, P. et al. CD38-induced metabolic dysfunction primes multiple myeloma cells for NAD+-lowering agents. Antioxidants (Basel) https://doi.org/10.3390/antiox12020494 (2023). 10.3390/antiox12020494

[28]

ClinVar: improving access to variant interpretations and supporting evidence

Melissa J Landrum, Jennifer M Lee, Mark Benson et al.

Nucleic Acids Research 2018 10.1093/nar/gkx1153

[29]

CADD-Splice—improving genome-wide variant effect prediction using deep learning-derived splice scores

Philipp Rentzsch, Max Schubach, Jay Shendure et al.

Genome Medicine 2021 10.1186/s13073-021-00835-9

[30]

Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease

Siddhartha Jaiswal, Pradeep Natarajan, Alexander J. Silver et al.

New England Journal of Medicine 2017 10.1056/nejmoa1701719

[31]

DeZern, A. E., Malcovati, L. & Ebert, B. L. CHIP, CCUS, and other acronyms: definition, implications, and impact on practice. Am. Soc. Clin. Oncol. Educ. Book 39, 400–410 (2019). 10.1200/edbk_239083

[32]

Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant

June-Wha Rhee, Raju Pillai, Tianhui He et al.

JAMA Cardiology 2024 10.1001/jamacardio.2023.4105

[33]

Testa, S. et al. Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias. Semin. Oncol. 49, 465–475 (2022). 10.1053/j.seminoncol.2022.11.001

[34]

Meier, J., Jensen, J. L., Dittus, C., Coombs, C. C. & Rubinstein, S. Game of clones: diverse implications for clonal Hematopoiesis in lymphoma and multiple myeloma. Blood Rev. 56, 100986 (2022). 10.1016/j.blre.2022.100986

[35]

Cook, G., Larocca, A., Facon, T., Zweegman, S. & Engelhardt, M. Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network. Leukemia 34, 2285–2294 (2020). 10.1038/s41375-020-0918-6

[36]

Clonal hematopoiesis in human aging and disease

Siddhartha Jaiswal, Benjamin L. Ebert

Science 2019 10.1126/science.aan4673

[37]

Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477–2487 (2014). 10.1056/nejmoa1409405

[38]

Stelmach, P. et al. Clonal hematopoiesis with DNMT3A and PPM1D mutations impairs regeneration in autologous stem cell transplant recipients. Haematologica 108, 3308–3320 (2023). 10.3324/haematol.2023.282992

[39]

Li, N. et al. Clonal haematopoiesis of indeterminate potential predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma. Br. J. Haematol. 201, 577–580 (2023). 10.1111/bjh.18716

[40]

Rodriguez, J. E., Micol, J. B. & Baldini, C. Exploring clonal hematopoiesis and its impact on aging, cancer, and patient care. Aging 15, 14507–14508 (2023). 10.18632/aging.205404

[41]

Zweegman, S. & Larocca, A. Frailty in multiple myeloma: the need for harmony to prevent doing harm. Lancet Haematol. 6, e117–e118 (2019). 10.1016/s2352-3026(19)30011-0

[42]

Mian, H. et al. The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review. Blood Cancer J. 13, 6 (2023). 10.1038/s41408-022-00779-2

[43]

Larocca, A., Cani, L., Bertuglia, G., Bruno, B. & Bringhen, S. New strategies for the treatment of older myeloma patients. Cancers (Basel) https://doi.org/10.3390/cancers15102693 (2023). 10.3390/cancers15102693

[44]

Libby, P. & Ebert, B. L. CHIP (Clonal Hematopoiesis of indeterminate potential): Potent and newly recognized contributor to cardiovascular risk. Circulation 138, 666–668 (2018). 10.1161/circulationaha.118.034392

Metrics

4

Citations

44

References

Details

Published: Nov 26, 2024
Vol/Issue: 14(1)
License: View

Authors

Division of Hematology with BMT, A.O.U. Policlinico “G.Rodolico-San Marco”, 95123 Catania, Italy

Hematology and Cellular Therapy Unit, IRCCS Ospedale Policlinico San Martino Genova Italy

Department of Hematology Businco Hospital Cagliari Italy

F

Francesco Di Raimondo

Department of Hematology, Hospital Ferrarotto, Catania, Italy;

9Clinic of Hematology, Department of Internal Medicine, University of Genoa, Genoa, Italy.; 10San Martino Hospital IRCCS, Genoa, Italy.

M

Michele Cea

Funding

Associazione Italiana per la Ricerca sul Cancro Award: IG #23438

International Myeloma Society (IMS) and Paula and Rodger Riney Foundation Award: Translational Research Award 2023

Cite This Article

Elisa Gelli, Claudia Martinuzzi, Debora Soncini, et al. (2024). Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysis. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-024-79748-7

Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysis

You May Also Like